Molecular Identification of Clinically Common and Uncommon Yeast Species

Shokohi, Tahereh; Moradi, Nasim; Badram, Laleh; Badali, Hamid; Ataollahi, Mohammad Reza; Afsarian, Mohammad Hosein

doi:10.5812/jjm.66240

Cited by 6 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MALDI-TOF MS-based identification of all isolates to the species level was performed according to Bruker Daltonics (Biotyper RTC software, version 3.0 (Bruker Daltonics, Bremen, Germany)) using the ethanol (EtOH)/ formic acid (FA) extraction protocol [ 9 , 10 ]. In addition, discrimination of the C. albicans species complex, i.e., C. albicans , C. dubliniensis , C. africana , and C. stellatoidea was performed by the amplification of the hyphal wall protein 1 (HWP1) gene as previously described [ 11 , 12 ].…”

Section: Methodsmentioning

confidence: 99%

Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles

Aslani¹,

Kokabi²,

Moradi³

et al. 2022

CMM

View full text Add to dashboard Cite

Background and Purpose: Vulvovaginal candidiasis (VVC) is an opportunistic infection due to Candida species, one of the most common genital tract diseases among reproductive-age women. The present study aimed to investigate the prevalence of VVC among non-pregnant women and identify the epidemiology of the involved Candida species with the evaluation of antifungal susceptibilities. Materials and Methods: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was performed to identify Candida species isolated from the genital tract of 350 non-pregnant women. Moreover, antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute broth microdilution method guidelines (M27-A3 and M27-S4). Results: Vaginal swab cultures of 119 (34%) women yielded Candida species. Candida albicans was the most frequently isolated species (68%), followed by Candida glabrata (19.2%). Voriconazole was the most active drug against all tested isolates showing an MIC50/MIC90 corresponding to 0.016/0.25 µg/mL, followed by posaconazole (0.031/1 µg/mL). Overall, resistance rates to fluconazole, itraconazole, and voriconazole were2.4%, 4.8% and, 0.8% respectively. However, posaconazole showed potent in vitro activity against all tested isolates. Conclusion: Results of the current study showed that for the effectual therapeutic outcome of candidiasis, accurate identification of species, appropriate source control, suitable antifungal regimens, and improved antifungal stewardship are highly recommended for the management and treatment of infection with Candida, like VVC.

show abstract

Section: Methodsmentioning

confidence: 99%

Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles

Aslani¹,

Kokabi²,

Moradi³

et al. 2022

CMM

View full text Add to dashboard Cite

show abstract

“…In 2 of those 30 studies (corresponding to 1 article, , the problem was due to a lack of information regarding the source attribution. In 19 studies (corresponding to 15 articles: Afsarian et al, 2018;Diba et al, 2018;Das et al, 2018;Hasan and Yassein, 2018;Jung et al, 2018;Kara et al, 2018;Khedri et al, 2018;Kaur et al, 2018;, the problem was due to predisposing factors in the exposed subject.…”

Section: Yeastsmentioning

confidence: 99%

“…For 32 of those 45 studies, no potential safety concern was reported, while a potential safety concern was described in the other 13 studies (corresponding to 11 articles: Diba et al, 2018;Das et al, 2018;Jung et al, 2018;Kara et al, 2018;Khedri et al, 2018;Afsarian et al, 2018;: 3 for C. famata (Das et al, 2018;Diba et al, 2018;, 7 for C. kefyr Diba et al, 2018;Khedri et al, 2018;, 1 for C. pelliculosa and 2 for Saccharomyces cerevisiae (Kara et al, 2018;. All these studies reported isolation of the QPS yeasts from opportunistic infections in patients with serious predisposing factors.…”

Section: Yeastsmentioning

confidence: 99%

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

Koutsoumanis¹,

Allende²,

Álvarez‐Ordóñez³

et al. 2019

EFS2

View full text Add to dashboard Cite

The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic preevaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit (TU) are, where possible and reasonable in number, reflected by 'qualifications' which should be assessed at the strain level by the EFSA's Scientific Panels. During the current assessment, no new information was found that would change the previously recommended QPS TUs and their qualifications. The list of microorganisms notified to EFSA from applications for market authorisation was updated with 47 biological agents, received between October 2018 and March 2019. Of these, 19 already had QPS status, 20 were excluded from the QPS exercise by the previous QPS mandate (11 filamentous fungi) or from further evaluations within the current mandate (9 notifications of Escherichia coli). Sphingomonas elodea, Gluconobacter frateurii, Corynebacterium ammoniagenes, Corynebacterium casei, Burkholderia ubonensis, Phaeodactylum tricornutum, Microbacterium foliorum and Euglena gracilis were evaluated for the first time. Sphingomonas elodea cannot be assessed for a possible QPS recommendation because it is not a valid species. Corynebacterium ammoniagenes and Euglena gracilis can be recommended for the QPS list with the qualification 'for production purposes only'. The following TUs cannot be recommended for the QPS list: Burkholderia ubonensis, due to its potential and confirmed ability to generate biologically active compounds and limited of body of knowledge; Corynebacterium casei, Gluconobacter frateurii and Microbacterium foliorum, due to lack of body of knowledge; Phaeodactylum tricornutum, based on the lack of a safe history of use in the food chain and limited knowledge on its potential production of bioactive compounds with possible toxic effects.

show abstract

“…This study was conducted on 110 yeast and yeastlike species isolated from the nail (n=46), skin (n=36), bronchoalveolar lavage (n=9), sputum (n=7), mouth (n=5), mucosa (n=3), vagina (n=2), ear discharge (n=1), and urine (n=1) during 8 months [12]. The isolates were obtained from the Reference Culture Collection of Invasive Fungi Research Center in Sari, Iran.…”

Section: Isolatesmentioning

confidence: 99%

“…The isolates were obtained from the Reference Culture Collection of Invasive Fungi Research Center in Sari, Iran. They had been previously identified through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), PCR amplification of hwp1 gene, and sequencing [12].…”

Section: Isolatesmentioning

confidence: 99%

In vitro activity of four triazole antifungal drugs against clinically common and uncommon yeast species

Aslani¹,

Shokohi²,

Ataollahi³

et al. 2019

CMM

Self Cite

View full text Add to dashboard Cite

Background and Purpose: Incidence of fungal infections caused by opportunistic fungal pathogens, such as yeasts and yeast-like species, has undergone an increase in otherwise healthy individuals. These pathogens account for high mortality and show reduced susceptibility to the routine antifungal drugs. Accordingly, antifungal susceptibility testing is an urgent need in the determination of the susceptibility spectrum of antifungals and selection of appropriate antifungal agents for the management of patients with fungal infection.Materials and Methods: The present study was conducted on 110 yeast strains belonging to 15 species recovered from clinical specimens. Susceptibility of the isolates to four antifungal drugs (i.e., fluconazole, itraconazole, voriconazole, and posaconazole) was tested according to the Clinical and Laboratory Standards Institute guidelines M27-A3 and M27-S4.Results: Fluconazole exhibited no activity against 4.3% (n=2) of C. albicans isolates, whereas the remaining 44 isolates had a minimum inhibitory concentration (MIC) range of 0.125-4 μg/ml. Voriconazole had the lowest geometric mean MIC (0.03 μg/ml) against all isolated yeast species, followed by posaconazole (0.07 μg/ml), itraconazole (0.10 μg/ml), and fluconazole (0.60 μg/ml). Overall, all of the isolates had reduced voriconazole MICs with a MIC range of 0.016-0.5 μg/ml, except for one isolate of C. albicans that had a MIC of 1 μg/ml. Candida haemulonii as a multidrug-resistant fungus showed a fluconazole MIC of > 64 μg/ml.Conclusion: The current study provides insight into the antifungal susceptibility profiles of clinically common and uncommon yeast species to four triazole antifungal agents. According to our findings, voriconazole was the most active agent. Awareness about antifungal susceptibility patterns is highly helpful in the selection of appropriate antifungal drugs and identification of the efficiency of the currently used agents.

show abstract

Molecular Identification of Clinically Common and Uncommon Yeast Species

Cited by 6 publications

References 38 publications

Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles

Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 10: Suitability of taxonomic units notified to EFSA until March 2019

In vitro activity of four triazole antifungal drugs against clinically common and uncommon yeast species

Contact Info

Product

Resources

About